XinGuangWei Medical Secures Nearly RMB 400 Million in Series B Funding to Accelerate Global Expansion and Files IPO Prospectus

VCBeat has learned that following the completion of its Series A financing in April this year, and with the accelerated advancement of R&D and commercialization of endoscopic products, Scivita Medical Technology Co., Ltd. (hereinafter referred to as “Scivita Medical”) announced today that it has secured nearly RMB 400 million in Series B financing.

This round of investors includes new institutional investors such as Hudson Bay Capital Management and Prime Capital, while existing shareholders Hillhouse Ventures, Lilly Asia Ventures, and Matrix Partners China continued to increase their support. Scivita Medical stated that the funds raised in this round will continue to be used for the research and development of innovative products in endoscopy and related fields, capacity expansion, and commercial promotion both domestically and internationally.

Since its inception, Scivita Medical has prioritized globalization as a core strategy, establishing R&D centers in Suzhou, China, and Tokyo, Japan. This dual-center approach facilitates the synchronized global development, patent application, regulatory registration, and commercialization of its products, with the aim of building a world-leading innovation platform for endoscopes and related fields. The successful completion of this financing round fully demonstrates both new investors and existing shareholders’ recognition of Scivita Medical’s future growth potential and their confidence in its sustained development.

Driven by factors such as the promotion of tiered diagnosis and treatment, the development of minimally invasive surgery, and population aging, market demand for endoscopes and their installation rate have risen rapidly. Scivita Medical has established a comprehensive product portfolio that includes both rigid and flexible endoscopes, reusable and single-use endoscopes, as well as white-light and fluorescence endoscopes.

Scivita Medical 4K Ultra-High-Definition Endoscopic Camera System

Currently, its commercialized products include 3D imaging devices, 4K medical endoscopic camera systems, integrated 4K-3D endoscopy systems, 4K rhinoscopes, 4K arthroscopes, single-use electronic hysteroscopes, single-use electronic cysto-pyeloscopes, and single-use electronic bronchoscopes. In the future, Scivita Medical will continue to innovate while promoting simultaneous regulatory approvals for its products in China, the United States, Japan, Europe, and other regions, thereby steadily expanding its global market presence.

Scivita Medical’s pace of innovation has consistently outpaced the market and led industry development, reflecting its robust R&D capabilities and confidence. Scivita Medical possesses globally advanced technologies, including ultra-high-definition imaging (such as 4K imaging), 3D imaging technologies (including monocular and binocular 3D), disposable endoscope technology, special light imaging technologies (such as fluorescence imaging), and ultra-thin endoscope imaging technology. In the future, Scivita Medical will integrate its existing technologies to create a diversified product portfolio featuring 4K fluorescence, 3D fluorescence, and other multimodal solutions.

Scivita Medical’s technological innovations are driven by the goal of addressing clinical pain points and developing high-quality products that truly meet the needs of clinicians. For instance, during the development of its 4K medical endoscopic camera system, Scivita Medical leveraged medical-engineering collaboration to identify clinical challenges such as lens fogging and smoke interference during laparoscopic procedures. The company successfully developed a heating function at the front end of the lens to effectively prevent fogging caused by temperature differences. Additionally, through advanced signal processing technology, it enabled a one-touch smoke removal feature on the camera control unit, effectively eliminating smoke interference and improving surgical efficiency.

Scivita Medical Single-Use Electronic Cystoureteroscope

Scivita Medical’s independently developed single-use endoscope not only effectively addresses the issue of cross-infection but also delivers image quality comparable to that of reusable endoscopes. Furthermore, Scivita Medical has fully incorporated ergonomic principles into its product development. The resulting single-use endoscope allows clinicians to operate it flexibly with either hand and accommodates different diagnostic scenarios, whether in a standing or sitting position. This design effectively reduces operator fatigue, enhances diagnostic and treatment efficiency, and ultimately benefits more patients.

In terms of imaging clarity, color fidelity, as well as endoscope maneuverability, transmission performance, and insertability, the clinical evaluation of Scivita Medical’s products has reached an international first-class level. In recent years, Scivita Medical’s products have been primarily sold to tertiary hospitals in China, represented by top-tier Grade 3A hospitals, benchmarking against international leading brands in product quality and efficacy. Looking ahead, in addition to adhering to its strategic goal of developing high-end domestic products, Scivita Medical will also launch popularized endoscopy systems tailored for hospitals at all levels, thereby extending the benefits of its internationally advanced products to healthcare institutions across China.

Looking ahead, Scivita Medical will continue to pursue a globalization strategy, deeply addressing clinical needs and pain points. By collaborating with global clinical experts, we aim to jointly advance the development of the endoscopy industry, making diagnosis and treatment safer, more effective, and more precise, thereby delivering tangible benefits to patients worldwide.